Aims & Scope

Journal of Advances in Leukemia (JAL) publishes original research, systematic reviews, and translational studies advancing the understanding, diagnosis, and treatment of leukemia and related hematologic malignancies.

Acute & Chronic Leukemia Molecular Pathogenesis Targeted Therapies Hematopoietic Stem Cell Transplantation Biomarker Discovery

We do NOT consider: General oncology without leukemia focus, non-hematologic malignancies, purely clinical case reports without mechanistic insights, or studies outside hematologic disease contexts.

●

Core Research Domains

Leukemia Biology & Pathogenesis Tier 1

Acute myeloid leukemia (AML) molecular mechanisms
Acute lymphoblastic leukemia (ALL) cellular biology
Chronic myeloid leukemia (CML) signaling pathways
Chronic lymphocytic leukemia (CLL) immunobiology
Leukemogenesis and clonal evolution
Oncogene function and tumor suppressor mechanisms

Typical Fit Example: "Novel FLT3-ITD mutation mechanisms driving AML progression through altered epigenetic regulation"

Diagnostics & Biomarkers Tier 1

Molecular diagnostic techniques for leukemia classification
Prognostic and predictive biomarker discovery
Minimal residual disease (MRD) detection methods
Cytogenetic and genomic profiling
Flow cytometry and immunophenotyping advances
Liquid biopsy and circulating tumor markers

Typical Fit Example: "Validation of next-generation sequencing panel for MRD monitoring in pediatric ALL with 0.01% sensitivity"

Therapeutic Strategies Tier 1

Targeted therapy development and optimization
Immunotherapy approaches (CAR-T, BiTEs, checkpoint inhibitors)
Chemotherapy protocols and drug resistance mechanisms
Tyrosine kinase inhibitors (TKIs) for CML and other leukemias
Epigenetic modifiers and differentiation therapy
Combination treatment strategies

Typical Fit Example: "Phase II trial results: BCL-2 inhibitor combined with hypomethylating agents in elderly AML patients"

Hematopoietic Stem Cell Biology Tier 1

Hematopoietic stem cell transplantation (HSCT) outcomes
Bone marrow microenvironment and niche interactions
Graft-versus-host disease (GVHD) mechanisms and prevention
Stem cell mobilization and engraftment
Leukemia stem cell identification and targeting
Post-transplant complications and management

Typical Fit Example: "Characterization of leukemia stem cell surface markers for selective therapeutic targeting in AML"

✦

Secondary Focus Areas

Related Hematologic Malignancies

Myelodysplastic syndromes (MDS)
Myeloproliferative neoplasms (MPN)
Lymphoproliferative disorders with leukemic phase
Plasma cell leukemia
Hairy cell leukemia

Supportive Care & Complications

Transfusion medicine in leukemia management
Infection prevention and treatment
Coagulation disorders in leukemia
Nutritional support and quality of life
Long-term survivorship issues

Computational & Systems Biology

AI/machine learning for leukemia diagnosis
Predictive modeling of treatment response
Multi-omics data integration
Network analysis of leukemia pathways
Bioinformatics tool development

Pediatric Leukemia

Childhood ALL and AML biology
Age-specific treatment protocols
Late effects of pediatric leukemia therapy
Genetic predisposition syndromes
Developmental considerations in treatment

⚡

Emerging Research Frontiers

Novel Therapeutic Modalities

Gene editing (CRISPR/Cas9) for leukemia treatment
Nanoparticle-based drug delivery systems
Synthetic biology approaches
Personalized medicine and pharmacogenomics

Microenvironment & Metabolism

Metabolic reprogramming in leukemia cells
Bone marrow niche remodeling
Immune microenvironment interactions
Mitochondrial dysfunction and targeting

Note: Manuscripts in emerging areas undergo additional editorial review to ensure methodological rigor and translational relevance to leukemia research.

Out of Scope

Solid Tumor Malignancies

Basal cell carcinoma, adenocarcinoma, adenoid cystic cancer - not hematologic malignancies

Non-Malignant Hematologic Disorders

Thalassemia, aplastic anemia, general anemia - unless directly related to leukemia pathogenesis or treatment

Lymphomas Without Leukemic Phase

Hodgkin's lymphoma, non-Hodgkin lymphoma, B-cell/T-cell lymphomas - unless presenting with leukemic involvement

General Biochemistry or Cell Biology

Studies without direct application to leukemia or hematologic malignancies

Purely Descriptive Case Reports

Single case reports without novel mechanistic insights, therapeutic innovations, or significant clinical implications

📄

Article Types & Editorial Priorities

Priority 1 Fast-Track Review

Original Research Articles Systematic Reviews & Meta-Analyses Methods & Protocols Clinical Trial Results

Priority 2 Standard Review

Short Communications Data Notes Perspectives & Commentaries Technical Notes

Rarely Considered Selective

Case Reports (only with novel insights) Opinion Pieces (by invitation)

Case reports must demonstrate significant mechanistic insights, novel therapeutic approaches, or rare presentations with broader clinical implications.

✅

Editorial Standards & Requirements

Reporting Guidelines

All manuscripts must adhere to appropriate reporting standards:

CONSORT STROBE PRISMA ARRIVE REMARK

Data Transparency

Authors must provide access to underlying data, code, and materials. Raw data deposition in public repositories (GEO, ArrayExpress, SRA) is required for omics studies. Clinical trial registration mandatory.

Ethics & Compliance

All human studies require IRB/ethics committee approval. Animal studies must follow ARRIVE guidelines and institutional IACUC approval. Informed consent documentation required for patient data.

Preprint Policy

We welcome submissions previously posted on recognized preprint servers (bioRxiv, medRxiv). Preprint posting does not affect consideration. Authors must disclose preprint DOI upon submission.

Editorial Decision Metrics

21 days Average Time to First Decision

32% Acceptance Rate

45 days Average Time to Publication

Open Article Processing Charges

Questions About Scope Fit?

If you are uncertain whether your manuscript aligns with our scope, we encourage pre-submission inquiries. Our editorial team will provide guidance within 5 business days.

Journal of Advances in Leukemia

Journal of Advances in Leukemia – Aim And Scope